Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities

BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets, today issued a shareholder update summarizing the Company’s progress through the first half of 2026, including its recently completed financing, continued advancement of NB1, its rhNELL-1-based bone graft product candidate, and further validation of its manufacturing and product stability profile.

“During the first half of 2026, we strengthened several of the fundamental drivers underlying NB1’s development and long-term value proposition: clinical execution, product stability, intellectual property protection and capital visibility,” said Bone Biologics CEO Jeff Frelick. “The extension of rhNELL-1’s validated shelf life to 29 months enhances our manufacturing and supply-chain flexibility, while the recent financing provides the runway to advance our first-in-human study and execute against our regulatory and operational priorities through Q2 2027. Collectively, we believe these achievements reduce execution risk, preserve strategic flexibility and position us to generate the clinical evidence necessary to further define NB1’s potential in spinal fusion.”